Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma

Ann Hematol. 2017 Nov;96(11):1959-1960. doi: 10.1007/s00277-017-3109-4. Epub 2017 Aug 22.

Authors

C Phipps¹, K W Yeoh², Y S Lee¹, C Nagarajan¹, S Gopalakrishnan¹, L P Ho³, W Y K Hwang¹, Y T Goh¹, N F Grigoropoulos⁴

Affiliations

¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
² Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
³ Department of Pathology, Singapore General Hospital, Singapore, Singapore.
⁴ Department of Haematology, Singapore General Hospital, Singapore, Singapore. [email protected].

PMID: 28831541
DOI: 10.1007/s00277-017-3109-4

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Brentuximab Vedotin
Combined Modality Therapy / methods
Cyclosporine / administration & dosage
Cyclosporine / adverse effects
Dose-Response Relationship, Drug
Epstein-Barr Virus Infections / complications
Epstein-Barr Virus Infections / therapy
Herpesvirus 4, Human / physiology
Humans
Immunoconjugates / administration & dosage
Immunosuppression Therapy / adverse effects
Immunosuppression Therapy / methods*
Kidney Transplantation / adverse effects
Lymphoma, Large-Cell, Immunoblastic / immunology
Lymphoma, Large-Cell, Immunoblastic / pathology
Lymphoma, Large-Cell, Immunoblastic / therapy
Lymphoma, Large-Cell, Immunoblastic / virology
Male
Neoplasm Staging
Plasmablastic Lymphoma / immunology
Plasmablastic Lymphoma / pathology
Plasmablastic Lymphoma / therapy*
Plasmablastic Lymphoma / virology*
Radiotherapy
Remission Induction

Substances

Immunoconjugates
Brentuximab Vedotin
Cyclosporine